



PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/589,029		
		Filing Date	June 21, 2007		
		First Named Inventor	David S. Lawrence		
		Art Unit	1653 1654		
		Examiner Name	Not yet assigned J. Ha		
Sheet	1	of	1	Attorney Docket Number	96700/1165

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/J.H./	1	Jirousek, M. et al. "(S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues: Isozyme Selective Inhibitors of Protein Kinase C β " J. Med. Chem. 39(14):2664-2671 (1996).	
	2	O'Brian, C.A. and Ward, N.E. "ATP-sensitive binding of melittin to the catalytic domain of protein kinase C" Molecular Pharmacology 36(3):355-359 (1989).	
	3	Martiny-Baron, G. et al. "Selective Inhibition of Protein Kinase C Isozymes by the Indolocarbazole Gö 6976" Journal of Biological Chemistry 268(13):9194-9197 (1993).	
	4	Eichholtz, T. et al. "A Myristoylated Pseudosubstrate Peptide, a Novel Protein Kinase C Inhibitor" Journal of Biological Chemistry 268(3):1982-1986 (1993).	
	5	Hofmann, J. "The potential for isoenzyme-selective modulation of protein kinase C" FASEB J. 11:649-669 (1997).	
/J.H./	6	Mackay, H.J. and Twelves, C.J. "Protein kinase C: a target for anticancer drugs?" J. Endocr. Relat. Cancer 10:389-396 (2003).	

Examiner Signature	/Julie Ha/	Date Considered	05/27/2010
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.